(P030) Metaplastic Breast Carcinoma at a Single Institution: Clinical-Pathologic Characteristics and Outcome
Similar to other reported series, the majority of our patients had triple-negative disease, and our patient population did not express the HER2/neu oncoprotein. Our predominant histology was squamous differentiation, whereas heterogeneity in histology is described in the literature. Despite high-grade disease, the outcomes in our study are favorable in comparison with previously reported series, although the follow-up is short.
Sharang Tenjarla, Sheema Chawla, MD, Jiqing Ye, MD, Brittany Heatherington, Lori Medeiros, MD, Peter Bushunow, MD; Rochester Regional Health System
OBJECTIVES: Metaplastic breast carcinomas (MBCs) are rare primary breast malignancies, constituting < 1% of all breast cancers. They are characterized by differentiation of the neoplastic epithelium into squamous cells and/or mesenchymal-like elements. There is a dearth of information on clinically relevant pathologic features and clinical outcomes for these rare tumors.
METHODS: A search of MBCs in the tumor registry and pathology archives of our center was performed. A review of the demographic and clinical-pathologic features and outcomes of all cases of MBC was performed between 2005 and 2014. Cases were reviewed retrospectively after institutional review board (IRB) approval.
RESULTS: A total of 32 cases were retrieved. Median age was 62 years (range: 42–79 yr). The median tumor size was 3.5 cm (range: 0.8–6.7 cm), and 72% (n = 23) of patients had grade 3 tumors. Histology outcomes showed: squamous in 13 (41%), adenosquamous in 4 (12%), osseous and chondroid in 6 (19%), and spindle cell/sarcomatoid in 9 patients (28%); 28 patients (88%) were triple-negative. Human epidermal growth factor receptor type 2 (HER2)/neu overexpression was not seen in any of the patients. A total of 19 patients underwent mastectomy (59%), and the rest underwent breast conservation surgery. The median follow-up was 17.5 months (range: 3–108 mo). Stage distribution was: stage IA in 11 (34%), IIA in 12 (38%), IIB in 7 (22%), and IIIA in 2 (6%) patients. At a median follow-up of 22 months, five patients had recurrence: one with local and four with distant (two brain, one bone, and one with multiple sites), two of whom are alive with disease. Overall, 28 patients (87%) were alive at last follow-up.
CONCLUSION: Similar to other reported series, the majority of our patients had triple-negative disease, and our patient population did not express the HER2/neu oncoprotein. Our predominant histology was squamous differentiation, whereas heterogeneity in histology is described in the literature. Despite high-grade disease, the outcomes in our study are favorable in comparison with previously reported series, although the follow-up is short.
Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
